The results showed that, compared to the control group, the semaglutide group significantly reduced systolic blood pressure (SBP) (mean difference [MD] 2.90, 95% confidence interval [CI] 3.70 to 2.11
Novo Nordisk sues Hims & Hers over copycat weight-loss drugs Subscribe to unlock this article Try unlimited access Only 1 for 4 weeks Then 59 per month
Note: Published safety data for TB-500 specifically is limitedmost evidence comes from Thymosin Beta-4 studies
Minoxidil's side effects are well documented
Semaglutide, a selective GLP-1 receptor agonist marketed as Ozempic, Wegovy, and Rybelsus, is one of the most extensively studied anti-obesity and anti-diabetes medications in history, with over 25,000 clinical trial participants and FDA approval for three distinct indications